Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Metastatic non-small-cell lung cancer (NSCLC) with activating EGFR mutations responds very well to first and second generation tyrosine-kinase inhibitors (TKI) including gefitinib, erlotinib and afatinib. Unfortunately, drug resistance will eventually develop and about half of the cases are secondar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Bin, Lee, Victor H. F., Chen, Lijiang, Ma, Lichun, Wang, Debby D., Yan, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529360/
https://www.ncbi.nlm.nih.gov/pubmed/28747773
http://dx.doi.org/10.1038/s41598-017-06632-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529360/
https://www.ncbi.nlm.nih.gov/pubmed/28747773
http://dx.doi.org/10.1038/s41598-017-06632-y

Ejemplares similares